Why the study?
Does fondaparinux or enoxaparin provide better cost-effectiveness as VTE prophylaxis in hip fracture surgery?
Does fondaparinux or enoxaparin provide better cost-effectiveness as VTE prophylaxis in hip fracture surgery?
Enoxaparin may offer cost advantages over fondaparinux for 7-day postoperative VTE prophylaxis in hip fracture patients, though both have similar costs per life year gained.
Answers are grounded in this paper and cite their sources.
Enoxaparin may offer cost advantages for 7-day hip fracture VTE prophylaxis; leaves open confirmation in larger randomized trials.
Hip fracture patients are at high risk of developing venous thromboembolic events (VTEs) postoperatively. Efficacy and safety data from a clinical trial comparing fondaparinux and enoxaparin as VTE prophylaxis were used to perform a cost assessment of these 2 agents. Incremental cost calculations demonstrate that enoxaparin offers advantages over fondaparinux when dosed for 7 days postoperatively in this patient population. Sensitivity analyses support this finding at the lower extreme; however, fondaparinux provides cost savings at the upper extreme. Cost per death averted and cost per life year gained are similar for these 2 agents in these patients.
No takes yet. Share an insight, caveat, or question.
Wade et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: